drugset / Trial / NCT00395421

Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin

NCT00395421

RandomizedParallel-groupSingle-blindTreatment

Summary

This study is being conducted to see if the investigational medication, valopicitabine, is safe to use in combination with ribavirin, a drug approved by the FDA for treating hepatitis C infection.

Timeline

Start
2006-10
Primary completion
2008-06
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject valopicitabine Unknown 200 mg
Background Peginterferon alfa-2a Protein / enzyme biologic 180 ug